Shopping Cart 0
Cart Subtotal
USD 0

Tricida Inc (TCDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750

Details

Summary

Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company. The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases. Its lead drug candidate TRC101, is under clinical development to treat metabolic acidosis a common complication of chronic kidney disease (CKD). Tricida plans to initiate a Phase III study to evaluate the safety and efficacy of TRC101 as a potential treatment for chronic metabolic acidosis associated with CKD. The company's portfolio of investors includes OrbiMed, Sibling Capital, Limulus Venture Partners, Longitude Capital and Vivo Capital. Tricida is headquartered in South San Francisco, California, the US.

Tricida Inc (TCDA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Tricida Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Tricida Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Tricida Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Tricida Raises USD25 Million in Debt Financing 10

Tricida Raises Additional USD57.5 Million in Series D Financing 11

Tricida Raises USD55 Million in Series C Financing Round 13

Tricida Raises USD30 Million in Series B Financing 15

Tricida Raises USD10 Million in Series A Financing 16

Tricida Raises USD 4.5 Million In Venture Financing 17

Equity Offering 18

Tricida Raises USD255.6 Million in IPO of Shares 18

Tricida Inc-Key Competitors 19

Tricida Inc-Key Employees 20

Tricida Inc-Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Financial Announcements 22

Aug 08, 2018: Tricida announces second quarter 2018 financial results and provides update on key initiatives 22

Corporate Communications 24

Jun 04, 2018: Tricida Names Kathryn Falberg As Board Director 24

Jan 08, 2018: Tricida Announces Hiring of Jeroen van Beek, Ph.D., as Chief Commercial Officer and Senior Vice President 25

Apr 11, 2017: Tricida Announces Hiring of Geoffrey Parker as Chief Financial Officer and Senior Vice President 26

Feb 15, 2017: Tricida appoints chief technology officer and senior vice president 27

Product News 28

02/15/2017: Tricida Announces Hiring of Wilhelm Stahl as Chief Technology Officer and Senior Vice President 28

01/09/2017: Tricida Announces Positive Topline Phase 1/2 Clinical Trial Results for TRC101 in 135 Subjects with Chronic Kidney Disease and Metabolic Acidosis 29

Clinical Trials 30

Jun 05, 2018: Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis 30

Nov 07, 2017: Tricida Announces Publication of TRC101 Phase 1/2 Study Results Demonstrating a Rapid and Significant Increase in Serum Bicarbonate in Chronic Kidney Disease Patients with Metabolic Acidosis 31

Nov 01, 2017: Tricida Announces Podium Presentation at ASN Kidney Week 2017 of TRC101 Phase 1/2 Study Results in Patients with Metabolic Acidosis Associated with Chronic Kidney Disease 32

Sep 28, 2017: Tricida Initiates Phase 3 Study of TRC101 for the Treatment of Metabolic Acidosis Associated with Chronic Kidney Disease 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

Tricida Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Tricida Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Tricida Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Tricida Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Tricida Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Tricida Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Tricida Raises USD25 Million in Debt Financing 10

Tricida Raises Additional USD57.5 Million in Series D Financing 11

Tricida Raises USD55 Million in Series C Financing Round 13

Tricida Raises USD30 Million in Series B Financing 15

Tricida Raises USD10 Million in Series A Financing 16

Tricida Raises USD 4.5 Million In Venture Financing 17

Tricida Raises USD255.6 Million in IPO of Shares 18

Tricida Inc, Key Competitors 19

Tricida Inc, Key Employees 20

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Tricida Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company. The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases. Its lead drug candidate TRC101, is under clinical development to treat metabolic acidosis a common complication of chronic kidney disease (CKD). Tricida plans to initiate a Phase III study to evaluate the safety and efficacy of TRC101 as a potential treatment for chronic metabolic acidosis associated with CKD. The company's portfolio of investors includes OrbiMed, Sibling Capital, Limulus Venture Partners, Longitude Capital and Vivo Capital. Tricida is headquartered in South San Francisco, California, the US.

Tricida Inc (TCDA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Tricida Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Tricida Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Tricida Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Tricida Raises USD25 Million in Debt Financing 10

Tricida Raises Additional USD57.5 Million in Series D Financing 11

Tricida Raises USD55 Million in Series C Financing Round 13

Tricida Raises USD30 Million in Series B Financing 15

Tricida Raises USD10 Million in Series A Financing 16

Tricida Raises USD 4.5 Million In Venture Financing 17

Equity Offering 18

Tricida Raises USD255.6 Million in IPO of Shares 18

Tricida Inc-Key Competitors 19

Tricida Inc-Key Employees 20

Tricida Inc-Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Financial Announcements 22

Aug 08, 2018: Tricida announces second quarter 2018 financial results and provides update on key initiatives 22

Corporate Communications 24

Jun 04, 2018: Tricida Names Kathryn Falberg As Board Director 24

Jan 08, 2018: Tricida Announces Hiring of Jeroen van Beek, Ph.D., as Chief Commercial Officer and Senior Vice President 25

Apr 11, 2017: Tricida Announces Hiring of Geoffrey Parker as Chief Financial Officer and Senior Vice President 26

Feb 15, 2017: Tricida appoints chief technology officer and senior vice president 27

Product News 28

02/15/2017: Tricida Announces Hiring of Wilhelm Stahl as Chief Technology Officer and Senior Vice President 28

01/09/2017: Tricida Announces Positive Topline Phase 1/2 Clinical Trial Results for TRC101 in 135 Subjects with Chronic Kidney Disease and Metabolic Acidosis 29

Clinical Trials 30

Jun 05, 2018: Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis 30

Nov 07, 2017: Tricida Announces Publication of TRC101 Phase 1/2 Study Results Demonstrating a Rapid and Significant Increase in Serum Bicarbonate in Chronic Kidney Disease Patients with Metabolic Acidosis 31

Nov 01, 2017: Tricida Announces Podium Presentation at ASN Kidney Week 2017 of TRC101 Phase 1/2 Study Results in Patients with Metabolic Acidosis Associated with Chronic Kidney Disease 32

Sep 28, 2017: Tricida Initiates Phase 3 Study of TRC101 for the Treatment of Metabolic Acidosis Associated with Chronic Kidney Disease 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

Tricida Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Tricida Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Tricida Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Tricida Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Tricida Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Tricida Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Tricida Raises USD25 Million in Debt Financing 10

Tricida Raises Additional USD57.5 Million in Series D Financing 11

Tricida Raises USD55 Million in Series C Financing Round 13

Tricida Raises USD30 Million in Series B Financing 15

Tricida Raises USD10 Million in Series A Financing 16

Tricida Raises USD 4.5 Million In Venture Financing 17

Tricida Raises USD255.6 Million in IPO of Shares 18

Tricida Inc, Key Competitors 19

Tricida Inc, Key Employees 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Tricida Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.